WO2005114213A3 - Diagnostics and therapeutics for diseases associated with g protein-coupled receptor npy1 (npy1) - Google Patents

Diagnostics and therapeutics for diseases associated with g protein-coupled receptor npy1 (npy1) Download PDF

Info

Publication number
WO2005114213A3
WO2005114213A3 PCT/EP2005/004906 EP2005004906W WO2005114213A3 WO 2005114213 A3 WO2005114213 A3 WO 2005114213A3 EP 2005004906 W EP2005004906 W EP 2005004906W WO 2005114213 A3 WO2005114213 A3 WO 2005114213A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
npy1
diseases
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2005/004906
Other languages
French (fr)
Other versions
WO2005114213A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2005114213A2 publication Critical patent/WO2005114213A2/en
Publication of WO2005114213A3 publication Critical patent/WO2005114213A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human NPY1 which is associated with the cardiovascular disorders, endocrine system and hormone disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, inflammatory diseases, respiratory Diseases, muscle-skeleton disorders, neurological disorders, reproduction disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, endocrine system and hormone disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, inflammatory diseases, respiratory Diseases, muscle-skeleton disorders, neurological disorders, reproduction disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of NPY1 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/004906 2004-05-21 2005-05-06 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor npy1 (npy1) WO2005114213A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04012030.5 2004-05-21
EP04012030 2004-05-21

Publications (2)

Publication Number Publication Date
WO2005114213A2 WO2005114213A2 (en) 2005-12-01
WO2005114213A3 true WO2005114213A3 (en) 2006-02-02

Family

ID=34979309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/004906 WO2005114213A2 (en) 2004-05-21 2005-05-06 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor npy1 (npy1)

Country Status (1)

Country Link
WO (1) WO2005114213A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571695A (en) * 1991-11-06 1996-11-05 Garvan Institute Of Medical Research Human neuropeptide Y-Y1 receptor
WO2001002364A1 (en) * 1999-07-06 2001-01-11 Astrazeneca Ab New npy antagonists
WO2002059377A2 (en) * 2001-01-24 2002-08-01 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20030153487A1 (en) * 2000-04-13 2003-08-14 Patrik Ernfors Use of npy y1 receptor antagonists in the treatment of inflammatory conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571695A (en) * 1991-11-06 1996-11-05 Garvan Institute Of Medical Research Human neuropeptide Y-Y1 receptor
WO2001002364A1 (en) * 1999-07-06 2001-01-11 Astrazeneca Ab New npy antagonists
US20030153487A1 (en) * 2000-04-13 2003-08-14 Patrik Ernfors Use of npy y1 receptor antagonists in the treatment of inflammatory conditions
WO2002059377A2 (en) * 2001-01-24 2002-08-01 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YONEDA MASASHI ET AL: "Central regulation of hepatic function by neuropeptides", JOURNAL OF GASTROENTEROLOGY, vol. 36, no. 6, June 2001 (2001-06-01), pages 361 - 367, XP002347019, ISSN: 0944-1174 *

Also Published As

Publication number Publication date
WO2005114213A2 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
WO2005106492A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
WO2005075665A3 (en) Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
WO2006008002A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 1 (klk1)
WO2004097421A3 (en) Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
WO2005095973A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2005106471A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
WO2005095972A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor etb (etb)
WO2005040828A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2005118840A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 10 (klk10)
WO2005106489A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 5 (ccr5)
WO2005095984A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled alpha 2a-adrenoceptor (adra2a)
WO2004099782A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39)
WO2005074969A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1)
WO2005114213A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor npy1 (npy1)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2004099783A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
WO2005108998A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor beta-3 adreno (adrb3)
WO2005040829A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2004106935A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 103 (gpr103)
WO2004099781A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor rdc1 (rdc1)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2005103690A3 (en) Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
WO2005103711A3 (en) Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 1 (cxcr1)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase